Skip to main content
Premium Trial:

Request an Annual Quote

Chiron to Use Serenex s Proteomics Technology

NEW YORK, Sept. 24 - Serenex today said that Chiron will use its protein-mining technology to help it uncover new drug targets.

 

Chiron will use Serenex's "functional proteome fractionation" technology and its Protein Mining tool to screen potential protein targets.

 

Serenex, which pocketed $15 million in a round of private-equity financing in mid-August, said it will hire 30 more scientists within a year to kick off a program to automate its proteomics platform. The company has also signed early-stage partnerships with Pharmacia and Pfizer and is in negotiations with two "recently-merged" companies, according to CEO Robert Dishman.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.